{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T15:40:28Z","timestamp":1740152428527,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,14]],"date-time":"2021-11-14T00:00:00Z","timestamp":1636848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,14]],"date-time":"2021-11-14T00:00:00Z","timestamp":1636848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI065298"],"award-info":[{"award-number":["AI065298"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To determine at two distinct time points the prevalence of resistance to ofloxacin (OFX), the representative class drug of fluoroquinolones (FQs), in <jats:italic>M. tuberculosis<\/jats:italic> isolates susceptible to first-line drugs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were 279 <jats:italic>M. tuberculosis<\/jats:italic> isolates from the two cohorts (2004\u20132005: 238 isolates; 2017: 41 isolates) that underwent OFX drug-susceptibility testing (critical concentration: 2\u00a0\u00b5g\/ml). Of 238 isolates in Cohort 1, no resistance to OFX was detected (95% CI 0\u20130.016); likewise, in Cohort 2, no resistance to OFX was detected in 41 isolates (95% CI 0\u20130.086). Our findings suggest that FQ use remains a viable option for the treatment of first-line drug-susceptible TB in Peru.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13104-021-05832-0","type":"journal-article","created":{"date-parts":[[2021,11,14]],"date-time":"2021-11-14T20:40:43Z","timestamp":1636922443000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6518-9719","authenticated-orcid":false,"given":"Alvaro","family":"Schwalb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Cachay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ericka","family":"Meza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"C\u00e1ceres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amondrea","family":"Blackman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda","family":"Maruri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy R.","family":"Sterling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Gotuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,14]]},"reference":[{"key":"5832_CR1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2174\/1568026033452537","volume":"3","author":"K Drlica","year":"2003","unstructured":"Drlica K, Malik M. Fluoroquinolones: action and resistance. Curr Top Med Chem. 2003;3:249\u201382. https:\/\/doi.org\/10.2174\/1568026033452537.","journal-title":"Curr Top Med Chem"},{"key":"5832_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.5588\/ijtld.16.0117","volume":"20","author":"TR Sterling","year":"2016","unstructured":"Sterling TR. Fluoroquinolones for the treatment and prevention of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016;20:42\u20137. https:\/\/doi.org\/10.5588\/ijtld.16.0117.","journal-title":"Int J Tuberc Lung Dis"},{"key":"5832_CR3","volume-title":"Consolidated guidelines on drug-resistant tuberculosis treatment","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. Consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019."},{"key":"5832_CR4","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1093\/cid\/ciw376","volume":"63","author":"P Nahid","year":"2016","unstructured":"Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63:e147\u201395. https:\/\/doi.org\/10.1093\/cid\/ciw376.","journal-title":"Clin Infect Dis"},{"key":"5832_CR5","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","volume":"384","author":"SE Dorman","year":"2021","unstructured":"Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med. 2021;384:1705\u201318. https:\/\/doi.org\/10.1056\/NEJMoa2033400.","journal-title":"N Engl J Med"},{"key":"5832_CR6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.amjmed.2004.09.015","volume":"118","author":"JA Linder","year":"2005","unstructured":"Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med. 2005;118:259\u201368. https:\/\/doi.org\/10.1016\/j.amjmed.2004.09.015.","journal-title":"Am J Med"},{"key":"5832_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.35663\/amp.2019.362.816","volume":"36","author":"J Gonz\u00e1lez-Mendoza","year":"2019","unstructured":"Gonz\u00e1lez-Mendoza J, Magui\u00f1a C, de Gonz\u00e1lez-Ponce FM. Resistance to antibacterial agents: a serious problem. Acta Med Peru. 2019;36:145\u201351.","journal-title":"Acta Med Peru."},{"key":"5832_CR8","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1016\/j.ijid.2010.11.008","volume":"15","author":"T-C Chen","year":"2011","unstructured":"Chen T-C, Lu P-L, Lin C-Y, Lin W-R, Chen Y-H. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis. 2011;15:e211\u20136. https:\/\/doi.org\/10.1016\/j.ijid.2010.11.008.","journal-title":"Int J Infect Dis"},{"key":"5832_CR9","doi-asserted-by":"crossref","unstructured":"Alarc\u00f3n V, Alarc\u00f3n E, Figueroa C, Mendoza-Ticona A. Tuberculosis en el Per\u00fa: Situaci\u00f3n epidemiol\u00f3gica, avances y desaf\u00edos para su control. Rev Peru Med Exp Salud Publica. 2017;34:299\u2013310. https:\/\/rpmesp.ins.gob.pe\/index.php\/rpmesp\/article\/view\/2384\/2777. Accessed 4 Mar 2019.","DOI":"10.17843\/rpmesp.2017.342.2384"},{"key":"5832_CR10","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3904\/kjim.2018.052","volume":"34","author":"H Kim","year":"2019","unstructured":"Kim H, Mok JH, Kang B, Lee T, Lee H-K, Jang HJ, et al. Trend of multidrug and fluoroquinolone resistance in Mycobacterium tuberculosis isolates from 2010 to 2014 in Korea: a multicenter study. Korean J Intern Med. 2019;34:344\u201352.","journal-title":"Korean J Intern Med"},{"key":"5832_CR11","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1183\/09031936.00036812","volume":"40","author":"GB Migliori","year":"2012","unstructured":"Migliori GB, Langendam MW, D\u2019Ambrosio L, Centis R, Blasi F, Huitric E, et al. Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones. Eur Respir J. 2012;40:814\u201322. https:\/\/doi.org\/10.1183\/09031936.00036812.","journal-title":"Eur Respir J"},{"key":"5832_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1164\/rccm.200901-0146OC","volume":"180","author":"RA Devasia","year":"2009","unstructured":"Devasia RA, Blackman A, Gebretsadik T, Griffin M, Shintani A, May C, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med. 2009;180:365\u201370. https:\/\/doi.org\/10.1164\/rccm.200901-0146OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"5832_CR13","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1093\/jac\/dkp096","volume":"63","author":"RA Devasia","year":"2009","unstructured":"Devasia RA, Blackman A, May C, Eden S, Smith T, Hooper N, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance. J Antimicrob Chemother. 2009;63:1173\u20138. https:\/\/doi.org\/10.1093\/jac\/dkp096.","journal-title":"J Antimicrob Chemother"},{"key":"5832_CR14","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1001\/archinte.167.21.2317","volume":"167","author":"PD Gaba","year":"2007","unstructured":"Gaba PD, Haley C, Griffin MR, Mitchel E, Warkentin J, Holt E, et al. Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease. Arch Intern Med. 2007;167:2317\u201322. https:\/\/doi.org\/10.1001\/archinte.167.21.2317.","journal-title":"Arch Intern Med"},{"key":"5832_CR15","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ijantimicag.2013.04.027","volume":"42","author":"YF van der Heijden","year":"2013","unstructured":"van der Heijden YF, Maruri F, Blackman A, Mitchel E, Bian A, Shintani AK, et al. Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones. Int J Antimicrob Agents. 2013;42:232\u20137. https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.04.027.","journal-title":"Int J Antimicrob Agents"},{"key":"5832_CR16","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1183\/09031936.00134712","volume":"42","author":"D Falzon","year":"2013","unstructured":"Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox HS, Holtz TH, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J. 2013;42:156\u201368. https:\/\/doi.org\/10.1183\/09031936.00134712.","journal-title":"Eur Respir J"},{"key":"5832_CR17","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.5588\/ijtld.12.0046","volume":"16","author":"YF van der Heijden","year":"2012","unstructured":"van der Heijden YF, Maruri F, Blackman A, Holt E, Warkentin JV, Shepherd BE, et al. Fluoroquinolone exposure prior to tuberculosis diagnosis is associated with an increased risk of death. Int J Tuberc Lung Dis. 2012;16:1162\u20137. https:\/\/doi.org\/10.5588\/ijtld.12.0046.","journal-title":"Int J Tuberc Lung Dis"},{"key":"5832_CR18","doi-asserted-by":"publisher","first-page":"5421","DOI":"10.1128\/AAC.00695-11","volume":"55","author":"H Takiff","year":"2011","unstructured":"Takiff H, Guerrero E. Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob Agents Chemother. 2011;55:5421\u20139. https:\/\/doi.org\/10.1128\/AAC.00695-11.","journal-title":"Antimicrob Agents Chemother"},{"key":"5832_CR19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/1471-2334-12-193","volume":"12","author":"S Pollett","year":"2012","unstructured":"Pollett S, Rocha C, Zerpa R, Pati\u00f1o L, Valencia A, Cami\u00f1a M, et al. Campylobacter antimicrobial resistance in Peru: a ten-year observational study. BMC Infect Dis. 2012;12:193. https:\/\/doi.org\/10.1186\/1471-2334-12-193.","journal-title":"BMC Infect Dis"},{"key":"5832_CR20","doi-asserted-by":"publisher","unstructured":"Monta\u00f1ez Valverde RA, Montenegro Idrogo JJ, Arenas Significaci\u00f3n FR, V\u00e1squez Alva R. Infecci\u00f3n urinaria alta comunitaria por E. coli resistente a ciprofloxacino: caracter\u00edsticas asociadas en pacientes de un hospital nacional en Per\u00fa. An Fac med. 2016;76:385. https:\/\/doi.org\/10.15381\/anales.v76i4.11408.","DOI":"10.15381\/anales.v76i4.11408"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-021-05832-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-021-05832-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-021-05832-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,14]],"date-time":"2021-11-14T20:43:43Z","timestamp":1636922623000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-021-05832-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,14]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5832"],"URL":"https:\/\/doi.org\/10.1186\/s13104-021-05832-0","relation":{},"ISSN":["1756-0500"],"issn-type":[{"type":"electronic","value":"1756-0500"}],"subject":[],"published":{"date-parts":[[2021,11,14]]},"assertion":[{"value":"9 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants had provided written informed consent, which authorized the use of stored <i>M. tuberculosis<\/i> isolates for TB studies. The study was approved by the Institutional Ethics Committee of Universidad Peruana Cayetano Heredia (SIDISI:200817) and Vanderbilt University Medical Center (VUMC)(IRB#081130).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"413"}}